Evidence map›Paper›PMID 32570885›Full record

ReviewNanomaterials (Basel, Switzerland)2020

Niosomal Drug Delivery Systems for Ocular Disease-Recent Advances and Future Prospects.

Saliha Durak, Monireh Esmaeili Rad, Abuzer Alp Yetisgin, Hande Eda Sutova, Ozlem Kutlu, Sibel Cetinel, Ali Zarrabi

Open access · goldAbstract readReview
In one paragraph

Review in Nanomaterials (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers.

0numbers the graph read from it
0cells of the map it votes in
65citing papers in PubMed
7.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

65 citing papers in PubMed, 175 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Recent advances in smart contact lenses.Biosensors & bioelectronics: X · 2026
    Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review

5 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Saliha DurakNanotechnology Research and Application Center (SUNUM), Sabanci University, Istanbul 34956, Turkey.ORCID 0000-0002-4064-7744
Monireh Esmaeili RadNanotechnology Research and Application Center (SUNUM), Sabanci University, Istanbul 34956, Turkey.
Abuzer Alp YetisginNanotechnology Research and Application Center (SUNUM), Sabanci University, Istanbul 34956, Turkey.ORCID 0000-0002-4581-9111
Hande Eda SutovaNanotechnology Research and Application Center (SUNUM), Sabanci University, Istanbul 34956, Turkey.
Ozlem KutluNanotechnology Research and Application Center (SUNUM), Sabanci University, Istanbul 34956, Turkey.
Sibel CetinelNanotechnology Research and Application Center (SUNUM), Sabanci University, Istanbul 34956, Turkey.ORCID 0000-0003-0248-9447
Ali ZarrabiNanotechnology Research and Application Center (SUNUM), Sabanci University, Istanbul 34956, Turkey.ORCID 0000-0003-0391-1769
Sabancı Üniversitesi · TR

Funding

SUNUM I.A.SN-19-00005 (S.C.) and I.A.SN-19-00001 (A.Z.)
6 · The paper itself

Abstract

The eye is a complex organ consisting of several protective barriers and particular defense mechanisms. Since this organ is exposed to various infections, genetic disorders, and visual impairments it is essential to provide necessary drugs through the appropriate delivery routes and vehicles. The topical route of administration, as the most commonly used approach, maybe inefficient due to low drug bioavailability. New generation safe, effective, and targeted drug delivery systems based on nanocarriers have the capability to circumvent limitations associated with the complex anatomy of the eye. Nanotechnology, through various nanoparticles like niosomes, liposomes, micelles, dendrimers, and different polymeric vesicles play an active role in ophthalmology and ocular drug delivery systems. Niosomes, which are nano-vesicles composed of non-ionic surfactants, are emerging nanocarriers in drug delivery applications due to their solution/storage stability and cost-effectiveness. Additionally, they are biocompatible, biodegradable, flexible in structure, and suitable for loading both hydrophobic and hydrophilic drugs. These characteristics make niosomes promising nanocarriers in the treatment of ocular diseases. Hereby, we review niosome based drug delivery approaches in ophthalmology starting with different preparation methods of niosomes, drug loading/release mechanisms, characterization techniques of niosome nanocarriers and eventually successful applications in the treatment of ocular disorders.

Indexed as

eye diseasenanocarrierniosomeocular drug delivery

Identifiers

PMID32570885
PMCPMC7353242
OpenAlexW3036547471

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.